| Identification | More | [Name]
Mitiglinide calcium | [CAS]
207844-01-7 | [Synonyms]
2H-ISOINDOLE-2-BUTANOIC ACID, OCTAHYDRO-GAMMA-OXO-ALPHA-(PHENYLMETHYL)-, CALCIUM SALT, DIHYDRATE, (AS,3AR,7AS)-
(aS,3aR,7aS)-Octahydro-gamma-oxo-alpha-(phenylmethyl)-2H-isoindole-2-butanoic acid calcium salt dihydrate
(S)-2-Benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric acid calcium salt dihydrate
Mitiglinide calcium
3006 MITIGLINIDE CALCIUM HYDRATE
2H-ISOINDOLE-2-BUTANOICACID,OCTAHYDRO-G-OXO-A-(PHENYLMETHYL)-,CALCIUMSALT,DIHYDRATE
2H-ISOINDOLE-2-BUTANOIC ACID, OCTAHYDRO-GAMMA-OXO-ALPHA-(PHENYLMETHYL)-, CALCIUM SALT, DIHYDRATE, (AS,3AR,7AS)-
(S)-2-Benzyl-4-oxo-4-(cis-perhydroisoindol-2-yl)butyric Acid Calcium Salt Hydrate
KAD-1229 Calcium Hydrate | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C38H52CaN2O8 | [MDL Number]
MFCD08460119 | [Molecular Weight]
704.91 | [MOL File]
207844-01-7.mol |
| Chemical Properties | Back Directory | [Appearance]
White Solid | [Melting point ]
179-185°C | [storage temp. ]
Inert atmosphere,Room Temperature | [solubility ]
Methanol (Slightly) | [form ]
Solid | [color ]
White | [Usage]
KAD-1229 binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells.
Antidiabetic | [InChI]
InChI=1/2C19H25NO3.Ca.2H2O/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;;;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);;2*1H2/q;;+2;;/p-2/t2*15-,16+,17-;;;/s3 | [InChIKey]
QEVLNUAVAONTEW-HNIWBTCONA-L | [SMILES]
N1(C[C@]2([H])CCCC[C@]2([H])C1)C(=O)C[C@H](CC1=CC=CC=C1)C(=O)O[Ca]OC(=O)[C@@H](CC1=CC=CC=C1)CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1.O.O |&1:2,8,14,29,42,48,r| | [CAS DataBase Reference]
207844-01-7(CAS DataBase Reference) |
| Hazard Information | Back Directory | [Description]
Mitiglinide calcium hydrate (KAD-1229) is an insulinotropic agent. Mitiglinide calcium hydrate is highly specific to the Kir6.2/SUR1 complex (the pancreatic beta-cell KATP channel). Mitiglinide is a drug for the treatment of type 2 diabetes. It may stimulate insulin secretion in beta-cells by closing off ATP dependant potassium ion channels. | [Chemical Properties]
White Solid | [Uses]
KAD-1229 binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells.
Antidiabetic | [Uses]
KAD-1229 binds to sulfonylurea receptors and inhibits the activity of ATP-sensitive K+ channel in MIN 6 cells. Antidiabetic. | [Mechanism of action]
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive K(+) (K(ATP)) channels in pancreatic beta-cells, and its early insulin release and short duration of action would be effective in improving postprandial hyperglycemia. | [in vivo]
Mitiglinide Calcium hydrate (1-3 mg/kg; p.o.) suppresses the increase in plasma glucose levels seen after a meal load and the area under the curve for plasma glucose levels (AUCglucose) up to 5 h after the meal load[2].
| Animal Model: | Pregnant Wistar rats (12 weeks)[2] | | Dosage: | 0.3 mg/kg, 1 mg/kg, 3 mg/kg | | Administration: | Oral administration | | Result: | Dose-dependently suppressed AUCglucose levels. |
| [storage]
Store at -20°C |
|
|